Clinical Trial Update: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the effect of dalcetrapib on cardiovascular risk in a genetically defined population after a recent acute coronary syndrome; recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Dalcetrapib (dalcetrapib)

Snippet

Sponsor: DalCor Pharmaceuticals | Conditions: Acute Coronary Syndrome | Phase 3 | Status: RECRUITING